Now showing items 1-7 of 7

    • Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients. 

      Farag, S; van Coevorden, F; Sneekes, E; Grunhagen, DJ; Reyners, AKL; Boonstra, PA; van der Graaf, WT; Gelderblom, HJ; Steeghs, N (2017-11)
      Although gastrointestinal stromal tumours (GIST) predominantly occur in older patients, data on treatment patterns in elderly GIST patients are scarce.Patients registered in the Dutch GIST Registry (DGR) from January 2009 ...
    • Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. 

      Machiela, MJ; Hofmann, JN; Carreras-Torres, R; Brown, KM; Johansson, M; Wang, Z; Foll, M; Li, P; Rothman, N; Savage, SA; Gaborieau, V; McKay, JD; Ye, Y; Henrion, M; Bruinsma, F; Jordan, S; Severi, G; Hveem, K; Vatten, LJ; Fletcher, T; Koppova, K; Larsson, SC; Wolk, A; Banks, RE; Selby, PJ; Easton, DF; Pharoah, P; Andreotti, G; Freeman, LEB; Koutros, S; Albanes, D; Mannisto, S; Weinstein, S; Clark, PE; Edwards, TE; Lipworth, L; Gapstur, SM; Stevens, VL; Carol, H; Freedman, ML; Pomerantz, MM; Cho, E; Kraft, P; Preston, MA; Wilson, KM; Gaziano, JM; Sesso, HS; Black, A; Freedman, ND; Huang, W-Y; Anema, JG; Kahnoski, RJ; Lane, BR; Noyes, SL; Petillo, D; Colli, LM; Sampson, JN; Besse, C; Blanche, H; Boland, A; Burdette, L; Prokhortchouk, E; Skryabin, KG; Yeager, M; Mijuskovic, M; Ognjanovic, M; Foretova, L; Holcatova, I; Janout, V; Mates, D; Mukeriya, A; Rascu, S; Zaridze, D; Bencko, V; Cybulski, C; Fabianova, E; Jinga, V; Lissowska, J; Lubinski, J; Navratilova, M; Rudnai, P; Szeszenia-Dabrowska, N; Benhamou, S; Cancel-Tassin, G; Cussenot, O; Bueno-de-Mesquita, HB; Canzian, F; Duell, EJ; Ljungberg, B; Sitaram, RT; Peters, U; White, E; Anderson, GL; Johnson, L; Luo, J; Buring, J; Lee, I-M; Chow, W-H; Moore, LE; Wood, C; Eisen, T; Larkin, J; Choueiri, TK; Lathrop, GM; Teh, BT; Deleuze, J-F; Wu, X; Houlston, RS; Brennan, P; Chanock, SJ; Scelo, G; Purdue, MP (2017-11)
      BACKGROUND:Relative telomere length in peripheral blood leukocytes has been evaluated as a potential biomarker for renal cell carcinoma (RCC) risk in several studies, with conflicting findings. OBJECTIVE:We performed an ...
    • Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. 

      Saad, F; Shore, N; Van Poppel, H; Rathkopf, DE; Smith, MR; de Bono, JS; Logothetis, CJ; de Souza, P; Fizazi, K; Mulders, PFA; Mainwaring, P; Hainsworth, JD; Beer, TM; North, S; Fradet, Y; Griffin, TA; De Porre, P; Londhe, A; Kheoh, T; Small, EJ; Scher, HI; Molina, A; Ryan, CJ (2015-10)
      Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.Investigation of outcomes for concomitant BTT in a post hoc ...
    • Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. 

      Andreassen, CN; Rosenstein, BS; Kerns, SL; Ostrer, H; De Ruysscher, D; Cesaretti, JA; Barnett, GC; Dunning, AM; Dorling, L; West, CML; Burnet, NG; Elliott, R; Coles, C; Hall, E; Fachal, L; Vega, A; Gómez-Caamaño, A; Talbot, CJ; Symonds, RP; De Ruyck, K; Thierens, H; Ost, P; Chang-Claude, J; Seibold, P; Popanda, O; Overgaard, M; Dearnaley, D; Sydes, MR; Azria, D; Koch, CA; Parliament, M; Blackshaw, M; Sia, M; Fuentes-Raspall, MJ; Ramon Y Cajal, T; Barnadas, A; Vesprini, D; Gutiérrez-Enríquez, S; Mollà, M; Díez, O; Yarnold, JR; Overgaard, J; Bentzen, SM; Alsner, J; International Radiogenomics Consortium (RgC) (2016-12)
      Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a well-powered ...
    • Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. 

      Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; Stuttle, C; Daley, F; Corbishley, CM; Dearnaley, DP; Hall, E; Somaiah, N; CHHiP Trial Investigators (2018-06)
      PURPOSE:To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ...
    • Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. 

      Kerns, SL; Dorling, L; Fachal, L; Bentzen, S; Pharoah, PDP; Barnes, DR; Gómez-Caamaño, A; Carballo, AM; Dearnaley, DP; Peleteiro, P; Gulliford, SL; Hall, E; Michailidou, K; Carracedo, Á; Sia, M; Stock, R; Stone, NN; Sydes, MR; Tyrer, JP; Ahmed, S; Parliament, M; Ostrer, H; Rosenstein, BS; Vega, A; Burnet, NG; Dunning, AM; Barnett, GC; West, CML; Radiogenomics Consortium (2016-08)
      Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. ...
    • Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt? 

      Capelan, M; Roda, D; Geuna, E; Rihawi, K; Bodla, S; Kaye, SB; Bhosle, J; Banerji, U; O'Brien, M; de Bono, JS; Popat, S; Yap, TA (2017-09)
      OBJECTIVES:Despite advances in novel drug development for patients with advanced non-small cell lung cancer (NSCLC), there are still only a limited number of approved treatments. We therefore evaluated the clinical outcomes ...